![Tempest Therapeutics, Inc. logo](/logos/TPST.webp)
Tempest Therapeutics, Inc.
NASDAQ:TPST
Overview | Financials
Company Name | Tempest Therapeutics, Inc. |
Symbol | TPST |
Currency | USD |
Price | 1.24 |
Market Cap | 31,257,672 |
Dividend Yield | 0% |
52-week-range | 0.17 - 9.77 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Stephen R. Brady J.D., LLM |
Website | https://www.tempesttx.com |
An error occurred while fetching data.
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD